Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Deep Learning Reconstruction of Lesion-Free Representations of the Brain in Multiple Sclerosis Patients
Multiple Sclerosis
P11 - Poster Session 11 (11:45 AM-12:45 PM)
3-006

In population-level studies, the comparison of MS brain MRIs with their synthetic lesion-free counterpart may highlight disease-specific variability which may provide insights into MS pathophysiology.

The purpose of this study is to recover 3D-T1 weighted brain MRI scans from Multiple Sclerosis (MS) patients to reproduce a homologous representation of their lesion-free brain.

A generative adversarial network (GAN) based on StyleGAN2 was trained to generate synthetic healthy brain scans from a 512-dimensional latent variable. Then, each MS brain was projected to this latent-space to recover the latent variable that generates the synthetic ‘healthy’ brain which is the most similar to the MS brain.

For model training, 3500 3D T1-weighted brain MRIs from healthy adults were pooled across the HCP, OASIS2 and IXI datasets. For evaluation, scans from 2398 MS patients from ADVANCE (NCT00906399) and ASCEND (NCT01416181) trials were used. All scans were skull-stripped, resampled to 2-mm isotropic voxel spacing, and intensity-normalized via min-max mapping to the range [-1, 1].

Model evaluation included visual inspection and quantitative measures: Mean Squared Error (MSE), Structural Similarity Metric (SSIM) and Peak Signal to Noise Ratio (PSNR) between the original MS brain scans and their synthetic lesion-free counterpart, excluding lesion mask areas.

We applied our method to 3D T1-weighted MRIs of MS patients to recover lesion-free brains with an isotropic resolution of 2mm. The generated lesion-free brain scans showed no MS lesions and displayed great similarity to the diseased brain outside of the MS lesion areas, as highlighted by the following metrics: SSIM = 0.99, PSNR = 34.5, MSE = 1.49e-3.

Our method reconstructed realistic lesion-free representations of 3D T1-weighted brain MRI scans of MS patients. This method could be generalizable to other neurological diseases.

Authors/Disclosures
Despoina Ioannidou, PhD (Therapanacea)
PRESENTER
Dr. Ioannidou has received personal compensation for serving as an employee of Therapanacea.
No disclosure on file
Bastien C. Caba (Biogen Canada) Mr. Caba has received personal compensation for serving as an employee of Therapanacea. Mr. Caba has received personal compensation for serving as an employee of Biogen. Mr. Caba has received personal compensation in the range of $50,000-$99,999 for serving as a Research Engineer with Therapanacea. Mr. Caba has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist II, ML/AI with Biogen.
Arie Gafson, MD, PhD (Biogen) Dr. Gafson has stock in Biogen.
No disclosure on file
Phoebe Jiang, PhD Dr. Jiang has received personal compensation for serving as an employee of Biogen. Dr. Jiang has stock in Biogen.
No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx.
Refaat E. Gabr, PhD Dr. Gabr has received personal compensation for serving as an employee of Biogen. Dr. Gabr has stock in Biogen.
No disclosure on file
Colm Elliott (NeuroRx Research) Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
No disclosure on file
Shibeshih Belachew, MD Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.